Kinetik (NYSE: KNTK), a prominent figure in the energy sector, has concluded a prosperous financial year marked by a remarkable achievement in adjusted EBITDA, soaring to $839 million, coupled with a record-breaking surge in processed gas volumes. Eyeing the horizon,...
Viking Therapeutics, Inc. (NASDAQ: VKTX), a biopharmaceutical leader in metabolic and endocrine disorder treatments, has set the stage for a significant financial stride. They’ve priced an underwritten public offering of 6,471,000 shares of common stock at...
During the Q4 2023 earnings call, Aaron’s Inc. (NYSE: AAN) unveiled a nuanced financial narrative marked by substantial e-commerce advancements and cost-saving initiatives, tempered by hurdles in its BrandsMart division and a scaled-back lease portfolio....
The FDA Grants Priority Review for Potential New Follicular Lymphoma Treatment, Epcoritamab, by Genmab A/S and AbbVie Genmab A/S (NASDAQ: GMAB) and AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for...
Fresh Del Monte Produce experienced a challenging last quarter, reporting revenues of $1.00 billion, marking a 4.8% year-on-year decline and missing analyst expectations by 6.5%. This downturn reflected a slower period for the company, falling short of both revenue...
Elevation Oncology, Inc. (NASDAQ:ELEV) has unveiled the extension of its Phase 1 clinical trial for EO-3021, a promising cancer therapy, marking the dosing of the inaugural patient in Japan. This expansion represents a strategic move in the company’s...
